Amyloidosis, Drug Safety, and a New Therapeutic Hope | Dr. Andy Vick

Amyloidosis, Drug Safety, and a New Therapeutic Hope | Dr. Andy Vick

Drug development is ultimately a balancing act: can a therapy create meaningful benefit without introducing unacceptable risk?

Dr. Andy Vick joins BioTalk Unzipped to discuss systemic amyloidosis, therapeutic antibodies, diagnostics, toxicology, rare disease research, and the transition from CRO life into biotechnology.

Andy explains the biology of systemic amyloidosis and describes Attralus Therapeutics’ approach to developing biologic therapeutics and diagnostics aimed at amyloid disease.

The conversation provides an accessible introduction to toxicology and why safety evaluation is fundamental to drug development. Andy also discusses one of the recurring challenges in rare disease research: finding animal models that adequately represent human disease.

He then reflects on moving from a contract research organization into a smaller biotechnology company and what changes, and what stays remarkably similar, when scientists move between CROs, pharmaceutical companies, and biotech.

New News takes the discussion into cancer immunology with an experimental mRNA-based approach to glioblastoma. The technology packages tumor-specific RNA inside lipid nanoparticles with the goal of generating a strong immune response against the cancer.

It is a conversation that spans fundamental drug safety, rare disease biology, career transitions, and some of the most ambitious approaches being investigated in oncology.

Chapters

02:22 - Dr. Vick’s charity work in Brazil

06:30 - Introduction to Attralus Therapeutics

07:41 - Developing treatments for systemic amyloidosis

10:35 - The role of toxicology in drug discovery and development

16:38 - Using animal models to study amyloidosis

22:06 - The history of Attralus and Dr. Vick’s transition from CRO to biotech

32:45 - New News: Promising results from an mRNA-based brain-cancer vaccine

Connect with Dr. Andy Vick

Dr. Andy Vick

https://www.linkedin.com/in/andy-vick-4467189/

Attralus Therapeutics

https://www.attralus.com/

Connect with the hosts

Dr. Chad Briscoe

https://www.linkedin.com/in/chadbriscoe/

Gregory Austin

https://www.linkedin.com/in/gregoryaustin1/

New News

Glioblastoma vaccine turns brain tumors from “cold” to “hot” in humans and dogs:

https://www.fiercebiotech.com/research/glioblastoma-vaccine-turns-brain-tumors-cold-hot-humans-and-dogs

Media credits

Pilot image: https://www.amazon.com/Military-Aircraft-Cockpit-Photograph-Picture/dp/B07Z2KM6KY

University of Florida: https://www.clickorlando.com/news/florida/2024/03/11/university-of-florida-axes-diversity-and-inclusion-office-under-gop-led-law-aimed-at-ridding-similar-programs/

Music: “CLARITY,” Mifune

Music provided by Slip.stream: https://slip.stream

https://get.slip.stream/KFCilm

Keywords

systemic amyloidosis, therapeutic antibodies, toxicology, drug discovery, rare disease, biotechnology, diagnostics, glioblastoma, mRNA vaccine, lipid nanoparticles

#biotechnology #toxicology #glioblastoma #braincancer #amyloidosis #drugdevelopment

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(47)

Is AI Changing Scientists? The Future of Pharma with Dr. Rob Dodge

Is AI Changing Scientists? The Future of Pharma with Dr. Rob Dodge

Rob Dodge says AI has made him an expert Python programmer, even though he never took a class in it. But does having new capabilities change what it means to be a scientist?Dr. Chad Briscoe sits down ...

2 Okt 35min

Do Clinical Trials Take Too Much Blood? Patient-Centric Sampling with Joleen White

Do Clinical Trials Take Too Much Blood? Patient-Centric Sampling with Joleen White

Clinical trials often collect far more blood than an assay actually needs. Dr. Joleen White asks a more disciplined question: What information is required to make a sound decision, and how little samp...

11 Sep 48min

Why Gene Therapy Is Still So Hard to Manufacture at Scale | Phillip Ramsey

Why Gene Therapy Is Still So Hard to Manufacture at Scale | Phillip Ramsey

Why is gene therapy still so difficult to manufacture at scale after decades of progress?Phillip Ramsey, Chief Technical Officer at Sangamo Therapeutics, joins BioTalk Unzipped for a candid conversati...

8 Aug 11min

Her Daughter’s Brain Tumor Turned Her Into a Biotech Founder | Tracy Ryan

Her Daughter’s Brain Tumor Turned Her Into a Biotech Founder | Tracy Ryan

A mother’s search for answers to her daughter’s relentless brain tumor led her into natural killer cell biology, cancer immunotherapy, and biotech entrepreneurship.Sponsored by Leucentra, https://leuc...

20 Jul 1h 4min

The Future of Oncology Drug Development | Dr. Lakshmi Amaravadi

The Future of Oncology Drug Development | Dr. Lakshmi Amaravadi

Oncology drug development is becoming more complex, and bioanalysis can no longer be treated as simple drug measurement.Sponsored by Leucentra, https://leucentra.com/Inspired by science, empowered by ...

11 Jun 29min

Active Machine Learning for Drug Discovery & Nanomedicine with Dr. Daniel Reker

Active Machine Learning for Drug Discovery & Nanomedicine with Dr. Daniel Reker

Can artificial intelligence help make cancer therapies safer, more targeted, and more effective?In this episode of BioTalk Unzipped, Gregory Austin sits down with Dr. Daniel Reker, Assistant Professor...

25 Apr 50min

Why Haven’t We Cured Cancer Yet? | Dr. Bob Liu Explains

Why Haven’t We Cured Cancer Yet? | Dr. Bob Liu Explains

Why haven’t we cured cancer yet? A Genentech scientist explains the real reason.In this episode of BioTalk Unzipped, Gregory Austin and Dr. Chad Briscoe sit down with Dr. Bob Liu, Senior Principal Sci...

19 Mar 1h

The Intersection of Biotech, Patent Law, and AI with Dr. Kate Neville, IP Attorney

The Intersection of Biotech, Patent Law, and AI with Dr. Kate Neville, IP Attorney

Recorded October 31, 2025In this episode of BioTalk Unzipped, Gregory Austin and Dr. Chad Briscoe sit down with Dr. Kate Neville, immunologist turned seasoned biotech patent attorney at Marshall, Gers...

16 Feb 52min

Populært innen Business og økonomi

stopp-verden
dine-penger-pengeradet
rss-penger-polser-og-politikk
e24-podden
rss-skravla-gar
rss-borsmorgen-okonominyhetene
rss-pa-konto
finansredaksjonen
pengepodden-2
pengesnakk
livet-pa-veien-med-jan-erik-larssen
utbytte
lederpodden
liberal-halvtime
rss-orjasater
okonomiamatorene
morgenkaffen-med-finansavisen
tid-er-penger-en-podcast-med-peter-warren
rss-markedspuls-2
rss-impressions-2